Semiparametric Piecewise Accelerated Failure Time Model for the Analysis of Immune-Oncology Clinical Trials
用于肿瘤免疫治疗临床试验的半参数分段加速失效时间模型
Effectiveness of immune-oncology chemotherapies has been presented in recent clinical trials. The Kaplan-Meier estimates of the survival functions of the immune therapy and the control often suggested the presence of the lag-time until the immune therapy began to act. It implies the use of hazard ratio under the proportional hazards assumption would not be appealing, and many alternatives have been investigated such as the restricted mean survival time. In addition to such…